Exabis Library
Welcome to the e-CCO Library!
P496: Impact of ulcerative colitis on costs, work productivity and quality of life: a prospective study in a single referral centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P496: Real-world outcomes of vedolizumab for inflammatory bowel disease post liver transplantation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P496: Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P497 Is mucosal healing sufficient paramater for anti-TNF discontinuation?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P497: Clinical features and outcomes of tuberculosis in inflammatory bowel disease patients treated with anti-TNF therapy as compared with the general population
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P497: Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P497: IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P497: Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologics
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P497: Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studies
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P497: Is early bowel resection better than medical therapy for ileocolonic Crohn's disease? A systematic review and meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P497: The value of endoscopic healing index monitoring for guiding infliximab dosing in patients with Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P498 Loss of response of anti-TNF in Crohn’s disease patients single-centre experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P498: A nationwide quality improvement program in children with Crohn's disease improves outcomes within 12 months
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P498: Crohn’s disease patient’s isolated classical monocytes are characterised by reduced secretion of Wnt-ligands affecting Paneth cell antimicrobial host defense
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P498: Diagnosing and differentiating iron deficiency in inflammatory disorders: still an unsolved mystery?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P498: Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P498: Rephrasing the question: a novel simple tool for a more accurate evaluation of inflammatory bowel disease patients’ adherence to therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P498: Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess: The Leeds Steroids study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P498: Ustekinumab Real World Evidence Study (UndieS): study design with information about positioning and the choice of ustekinumab
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P499 Objectively assessed disease activity during ustekinumab treatment in a nationwide real-life Crohn’s disease cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM